Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).

Kristina Lindemann,Philip J Beale,Emma Rossi,Jeff C Goh,Michelle M Vaughan,Meaghan E Tenney,Julie K Martyn,Dirkje Sommeijer,Jose L Iglesias,Gabriel Kremmidiotis,Jeremy Simpson,Elizabeth Doolin,Tina C Lavranos,Annabell Leske, Anneso S Veillard,David Espinoza,Martin R Stockler,Danny Rischin

Cancer chemotherapy and pharmacology（2019）

引用 5|浏览72

暂无评分

摘要

We have established that BNC105P 12 mg/m with gemcitabine 1000 mg/m and carboplatin AUC4 is the recommended dose level and has an acceptable toxicity profile. Further exploration of BNC105P in the ovarian cancer setting is planned.

查看译文

关键词

BNC105P,Vascular disrupting agent (VDA),Ovarian cancer,Phase I,Gemcitabine,Carboplatin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要